Patents
US patents through Dec 31, 2025 · PatentsView, from the USPTO’s Open Data Portal · read Oct 27, 2026
52 patents granted to the 2 names below, as the owner printed on each patent when it was granted. A later sale, a lapse or an expiry is not read, so this is what was granted to vTv Therapeutics Inc.’s names, not what it holds today.
Patents granted
52
52 utility, 1976 to Dec 31, 2025
Granted in 2025
2
Against 4 in 2024 and 2 in 2023
Applications published
65
4 of them in 2025
Names they are printed under
2
its own name
By yearGrantedApplications published
'15'16'17'18'19'20'21'22'23'24'25
Each pair is one calendar year. Applications are published about eighteen months after filing, so the newest years read low.
What they are aboutgrants since 2021
Pharmaceuticals13
Organic fine chemistry5
The main technology area of each patent, in the World Intellectual Property Organization’s 35 fields.
Under which name2 counted
vTv Therapeutics LLC its own name
named as the applicant on its applications, in US
65 publishedVTV THERAPEUTICS LLC its own name
US, as the owner printed on each patent
0 published
Newest grantseach row opens the USPTO’s own copy
| Granted | Patent | Title | Field | Owner as printed |
|---|
| Nov 25, 2025 | 12,479,808 | Salts or co-crystals of {2-[3-cyclohexyl-3-(trans-4-propoxy-cyclohexyl)-ureido]-thiazol-5-ylsulfanyl}-acetic acid and uses thereof | Pharmaceuticals | VTV THERAPEUTICS LLC |
| Aug 19, 2025 | 12,391,658 | Sulfoxide and sulfone glucokinase activators and methods of use thereof | Organic fine chemistry | VTV THERAPEUTICS LLC |
| Sep 17, 2024 | 12,091,407 | Substituted fused imidazole derivatives, pharmaceutical compositions, and methods of use thereof | Pharmaceuticals | VTV THERAPEUTICS LLC |
| May 7, 2024 | 11,974,989 | Therapeutic uses of glucokinase activators in combination with insulin or insulin analogs | Pharmaceuticals | VTV THERAPEUTICS LLC |
| Apr 30, 2024 | 11,970,457 | Metabolites of [3-(4-(2-butyl-1-[4-(4-chloro-phenoxy)-phenyl]-1H-imidazol-4-yl)-phenoxy)-propyl]-diethyl-amine | Organic fine chemistry | VTV THERAPEUTICS LLC |
| Jan 30, 2024 | 11,883,383 | Pharmaceutically acceptable salts of [3-(4- {2-butyl-1-[4-(4-chloro-phenoxy)-phenyl]-1H-imidazol-4-yl} -phenoxy)-propyl]-diethyl-amine | Organic fine chemistry | VTV THERAPEUTICS LLC |
| Dec 5, 2023 | 11,833,136 | Therapeutic uses of glucokinase activators in combination with insulin or insulin analogs | Pharmaceuticals | VTV THERAPEUTICS LLC |
| May 16, 2023 | 11,649,230 | Substituted fused imidazole derivatives, pharmaceutical compositions, and methods of use thereof | Pharmaceuticals | VTV THERAPEUTICS LLC |
| Dec 13, 2022 | 11,524,942 | Metabolites of [3-(4-{2-butyl-1-[4-(4-chloro-phenoxy)-phenyl]-1H-imidazol-4 yl}-phenoxy)-propyl]-diethyl-amine | Organic fine chemistry | VTV THERAPEUTICS LLC |
| Aug 23, 2022 | 11,420,942 | Crystalline forms of [3-(4- {2-butyl-1-[4-(4-chloro-phenoxy)-phenyl]-1H-imidazol-4-yl} -phenoxy)-propyl]-diethyl-amine | Organic fine chemistry | VTV THERAPEUTICS LLC |
Newest applications publishedan application is a clue, never a plan
| Published | Application | Title | Field | Owner as printed |
|---|
| Nov 27, 2025 | 2025/0360139 | USE OF A PPAR-DELTA AGONIST FOR REDUCING LOSS OF MUSCLE STRENGTH, MUSCLE MASS, OR TYPE I MUSCLE FIBERS IN AN IMMOBILIZED LIMB | Pharmaceuticals | vTv Therapeutics LLC |
| Oct 30, 2025 | 2025/0332157 | SOLID COMPOSITION OF GLP-1 RECEPTOR AGONIST | Pharmaceuticals | vTv Therapeutics LLC |
| Oct 23, 2025 | 2025/0325536 | THERAPEUTIC USES OF GLP1R AGONISTS | Pharmaceuticals | vTv Therapeutics LLC |
| Sep 18, 2025 | 2025/0288681 | SOLID COMPOSITIONS COMPRISING A GLUCOKINASE ACTIVATOR AND METHODS OF MAKING AND USING THE SAME | Pharmaceuticals | vTv Therapeutics LLC |
| Jul 25, 2024 | 2024/0245656 | THERAPEUTIC USES OF GLUCOKINASE ACTIVATORS IN COMBINATION WITH INSULIN OR INSULIN ANALOGS | Pharmaceuticals | vTv Therapeutics LLC |
| Nov 30, 2023 | 2023/0382921 | Amorphous Form of Isoquinoline Derivative | Pharmaceuticals | vTv Therapeutics LLC |
| Oct 5, 2023 | 2023/0312559 | CRYSTALLINE FORM OF HYDROCHLORIDE SALT OF QUINOLINE DERIVATIVE | Pharmaceuticals | vTv Therapeutics LLC |
| Oct 5, 2023 | 2023/0312548 | SUBSTITUTE FUSED IMIDAZOLE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF USE THEREOF | Pharmaceuticals | vTv Therapeutics LLC · patent 12,091,407 granted from it |
| Aug 24, 2023 | 2023/0265089 | QUINOLINE DERIVATIVES, PHARMACEUTICALLY ACCEPTABLE SALTS, AND METHODS OF USE THEREOF | Pharmaceuticals | vTv Therapeutics LLC |
| Jul 13, 2023 | 2023/0219910 | CRYSTALLINE FORMS OF {2-[3-CYCLOHEXYL-3-(TRANS-4-PROPOXY-CYCLOHEXYL)-UREIDO]-THIAZOL-5-YLSULFANYL}-ACETIC ACID AND USES THEREOF | Pharmaceuticals | vTv Therapeutics LLC |
What it applied for, 2024 to 2025: Pharmaceuticals 5.
A patent is counted where the owner printed on it when it was granted carries the company’s own name, a former name, the name of a subsidiary its annual report lists, or its own name with a patent-holding phrase (Technology Licensing, Intellectual Property and the like), once the legal form, case and punctuation are set aside, and prints a country that name counts in. PatentsView’s data are published under the Creative Commons Attribution 4.0 licence. Source: PatentsView's granted patents and pre-grant publications, disambiguated, from the USPTO's Open Data Portal, through Dec 31, 2025, read Oct 27, 2026.